par Desmedt, Christine 
;Di Leo, Angelo ;Azambuja, Evandro ;Larsimont, Denis ;Haibe-Kains, Benjamin ;Selleslags, Jean;Delaloge, Suzette;Duhem, Caroline;Kains, Jean-Pierre;Carly, Birgit;Maerevoet, Marie ;Vindevoghel, Anita;Rouas, Ghizlane;Lallemand, Françoise;Durbecq, Virginie ;Cardoso, Fatima ;Salgado, Roberto;Kraft Rovere, Rodrigo ;Bontempi, Gianluca ;Michiels, Stefan ;Buyse, Marc;Nogaret, Jean-Marie ;Qi, Yuan;Symmans, Fraser;Pusztai, Lajos;D'Hondt, Veronique ;Piccart-Gebhart, Martine ;Sotiriou, Christos
Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04
;Di Leo, Angelo ;Azambuja, Evandro ;Larsimont, Denis ;Haibe-Kains, Benjamin ;Selleslags, Jean;Delaloge, Suzette;Duhem, Caroline;Kains, Jean-Pierre;Carly, Birgit;Maerevoet, Marie ;Vindevoghel, Anita;Rouas, Ghizlane;Lallemand, Françoise;Durbecq, Virginie ;Cardoso, Fatima ;Salgado, Roberto;Kraft Rovere, Rodrigo ;Bontempi, Gianluca ;Michiels, Stefan ;Buyse, Marc;Nogaret, Jean-Marie ;Qi, Yuan;Symmans, Fraser;Pusztai, Lajos;D'Hondt, Veronique ;Piccart-Gebhart, Martine ;Sotiriou, Christos Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04
Article révisé par les pairs
| Résumé : | Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER) -negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-α (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. |
